GWS
MIRM icon

Glassman Wealth Services’s Mirum Pharmaceuticals MIRM Stock Holding History

Glassman Wealth Services’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-8
Closed – – 1867
2022
Q2 		$0 Buy
+8
New +$189 ﹤0.01% 1876

Other funds holding MIRM

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RVM
RiverVest Venture Management St. Louis, Missouri $6.84M AUM 7.71% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CCM
Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Glassman Wealth Services's MIRM Position: Q3 2022 in Review

Glassman Wealth Services sold out of Mirum Pharmaceuticals (MIRM) in Q3 2022, closing a stake of 8 shares.

Glassman Wealth Services first reported a position in MIRM in Q2 2022 and held it in 1 quarter. The position peaked at $0 in Q2 2022. 112 funds tracked by Wall St. Rank hold MIRM as of Q3 2022.

  • Glassman Wealth Services reported no remaining Mirum Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Glassman Wealth Services sold 8 Mirum Pharmaceuticals shares in Q3 2022.
  • Glassman Wealth Services first reported a position in Mirum Pharmaceuticals in Q2 2022 and held it in 1 quarter.
  • Glassman Wealth Services's Mirum Pharmaceuticals position peaked at $0 in Q2 2022.
  • 112 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q3 2022.

Based on Glassman Wealth Services's 13F filing for Q3 2022, filed 9 Nov 2022.